Delaware
|
000-29169
|
98-0178636
|
||
(State
or other
jurisdiction
of
Incorporation)
|
(Commission
File
Number)
|
(I.R.S
Employer
Identification
No.)
|
||
33
Harbour Square, Suite 202, Toronto, Ontario
Canada
|
M5J
2G2
|
|||
(Address
of principal executive offices)
|
(Zip
Code)
|
¨
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
1.01
|
Entry
into a Material Definitive
Agreement.
|
Item 9.01
|
Financial Statements and
Exhibits
|
Exhibit
Number
|
Description
|
|
10.1
|
Limited
Liability Company Ownership Interest Purchase Agreement by and between
Generex Biotechnology Corporation, Global Medical Direct, LLC and Joseph
Corso, Jr., Robert S. Shea and Mark Franz
|
|
99.1
|
Press
release issued by Generex Biotechnology Corporation dated October 11,
2010
|
GENEREX
BIOTECHNOLOGY CORPORATION.
|
|
Date:
October 11, 2010
|
/s/ Rose C. Perri
|
Rose
C. Perri
Chief
Operating Officer
|
|
/s/ John P. Barratt
|
|
John
P. Barratt
|
|
Chairman
|
Exhibit
Number
|
Description
|
|
10.1
|
Limited
Liability Company Ownership Interest Purchase Agreement by and between
Generex Biotechnology Corporation, Global Medical Direct, LLC and Joseph
Corso, Jr., Robert S. Shea and Mark Franz
|
|
99.1
|
Press
release issued by Generex Biotechnology Corporation dated October 11,
2010
|